BFKB8488A

DRUG3 trials

Sponsors

Genentech, Inc.

Conditions

Diabetes Mellitus, Type 2Insulin ResistanceNon-Alcoholic Fatty Liver DiseaseNon-alcoholic Steatohepatitis

Phase 1

Study to Evaluate Safety, Tolerability, and Pharmacokinetics of BFKB8488A in Otherwise Healthy Overweight and Obese Participants With Likely Insulin Resistance

CompletedNCT02593331

Genentech, Inc.Insulin Resistance

Start: 2015-10-29End: 2017-03-28Updated: 2018-05-01

A Multiple Ascending Dose Study to Evaluate Safety and Tolerability of BFKB8488A in Participants With Type 2 Diabetes Mellitus and Participants With Non-Alcoholic Fatty Liver Disease

CompletedNCT03060538

Genentech, Inc.Diabetes Mellitus, Type 2, Non-Alcoholic Fatty Liver Disease

Start: 2017-03-05End: 2019-12-13Updated: 2020-03-27

Phase 2

A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of BFKB8488A Compared With Placebo in Participants With Non-Alcoholic Steatohepatitis

TerminatedNCT04171765

Genentech, Inc.Non-alcoholic Steatohepatitis

Start: 2020-09-30End: 2023-01-23Updated: 2024-04-16

Related Papers

Clinical Trial: A Phase 2b Study to Evaluate the Efficacy and Safety of MK-3655 in Individuals With Pre-Cirrhotic MASH.

2025-02-216 citations

Fibroblast growth factor receptor 1/Klothoβ agonist BFKB8488A improves lipids and liver health markers in patients with diabetes or NAFLD: A phase 1b randomized trial

Hepatology2022-08-2228 citations